Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) ; volume:79 ; number:4 ; day:11 ; month:3 ; year:2017 ; pages:651-660 ; date:4.2017
Cancer chemotherapy and pharmacology ; 79, Heft 4 (11.3.2017), 651-660, 4.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Yamazaki, Naoya
- Beteiligte Personen und Organisationen
-
Takenouchi, Tatsuya
Fujimoto, Manabu
Ihn, Hironobu
Uchi, Hiroshi
Inozume, Takashi
Kiyohara, Yoshio
Uhara, Hisashi
Nakagawa, Kazuhiko
Furukawa, Hiroshi
Wada, Hidefumi
Noguchi, Kazuo
Shimamoto, Takashi
Yokota, Kenji
SpringerLink (Online service)
- DOI
-
10.1007/s00280-016-3237-x
- URN
-
urn:nbn:de:1111-201704132793
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
2025-08-14T10:58:50+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yamazaki, Naoya
- Takenouchi, Tatsuya
- Fujimoto, Manabu
- Ihn, Hironobu
- Uchi, Hiroshi
- Inozume, Takashi
- Kiyohara, Yoshio
- Uhara, Hisashi
- Nakagawa, Kazuhiko
- Furukawa, Hiroshi
- Wada, Hidefumi
- Noguchi, Kazuo
- Shimamoto, Takashi
- Yokota, Kenji
- SpringerLink (Online service)
Ähnliche Objekte (12)
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
3475
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Nr. 3475
Nr. 3475
Nr. 3475
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Gebäudebuch 2995-3475
Nr. S 3475
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
3475
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Nr. 3475
Nr. 3475
Nr. 3475
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Gebäudebuch 2995-3475
Nr. S 3475
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
3475
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Nr. 3475
Nr. 3475
Nr. 3475
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Gebäudebuch 2995-3475